Agenus Inc. filings document the regulatory record for a clinical-stage immuno-oncology company developing antibody-based cancer therapies, led by the BOT+BAL program of botensilimab and balstilimab. Its Form 8-K reports cover periodic financial results, clinical-program and access-program updates, material agreements, securities-related amendments and the completed disposition of manufacturing assets with related license arrangements.
Proxy and governance filings describe board matters, executive compensation, shareholder voting items and equity awards. Other event reports document officer appointments, capital-structure changes, unregistered securities activity and legal or regulatory matters affecting the company's public-company disclosures.
Agenus (NASDAQ: AGEN) filed a routine Form 4 disclosing an equity award to Christine M. Klaskin, the company’s Principal Financial and Accounting Officer. On 06/17/2025, Klaskin was granted 7,250 stock options with a strike price of $3.02 per share under the 2019 Amended & Restated Equity Incentive Plan. The award had been approved by shareholders the same day. One-third of the options vest on 05/28/2026, with the balance vesting in equal quarterly installments thereafter, and the options expire on 05/28/2035. No shares were sold or otherwise disposed of, and Klaskin’s beneficial ownership increased by the option amount. The transaction appears to be a standard, non-material compensation grant rather than a market-moving insider trade.